Showing results (161-170 of 438) with videos related to
Sort By:
Pageof 44
Cancer Cell International|October 2, 2019
Correction to: Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastasesMatteo Fassan, Luca Vianello, Diana Sacchi, et al.Journal for Immunotherapy of Cancer|May 31, 2024
Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 studyMichael J Overman, Fabio Gelsomino, Massimo Aglietta, et al.BMC Cancer|January 27, 2018
The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patientsFrancesca Battaglin, Marta Schirripa, Federica Buggin, et al.Cancers|October 23, 2021
A Real-World Application of Liquid Biopsy in Metastatic Colorectal Cancer: The Poseidon StudyLetizia Procaccio, Francesca Bergamo, Francesca Daniel, et al.The New England Journal of Medicine|October 23, 2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancerFotios Loupakis, Chiara Cremolini, Gianluca Masi, et al.British Journal of Cancer|July 13, 2021
CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studiesRoberto Moretto, Daniele Rossini, Veronica Conca, et al.European Journal of Cancer (Oxford, England : 1990)|August 31, 2024
BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancerMargherita Ambrosini, David Tougeron, Dominik Modest, et al.ESMO Open|December 7, 2017
Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical studyChiara Cremolini, Filippo Pietrantonio, Gianluca Tomasello, et al.Journal of Cancer Research and Clinical Oncology|March 21, 2021
Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysisAndrea Casadei-Gardini, Lorenza Rimassa, Margherita Rimini, et al.Clinical Colorectal Cancer|August 25, 2021
Long Term Survival With Regorafenib: REALITY (Real Life in Italy) Trial - A GISCAD StudyEleonora Lai, Marco Puzzoni, Pina Ziranu, et al.Pageof 44